7 completed, 1 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow David Rizzieri, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant LMP2A-loaded conventional DC vaccine, DUK-CPG-001 - Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Phase 2 | Withdrawn | David Rizzieri, MD | 2016-12-01 | 2016-11-01 | |
| Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) Lenalidomide + Plerixafor (+ Rituximab) - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Completed | David Rizzieri, MD | 21 | 2012-01-01 | 2018-02-05 |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Non-myeloablative Stem Cell Transplantation - Hodgkin's Disease, Non Hodgkin's Lymphoma | Phase 2 | Completed | David Rizzieri, MD | 264 | 2008-02-01 | 2014-06-02 |
| PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma PTK787 - Lymphoma, Large-Cell, Diffuse | Phase 2 | Terminated | David Rizzieri, MD | 20 | 2005-11-01 | 2014-12-09 |
| Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath Campath Purged Non-myeloablative ASCT - Lymphoma, Myeloma | Phase 2 | Completed | David Rizzieri, MD | 48 | 2005-05-01 | 2016-06-24 |
| Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT NK Cell infusion using CD56 monoclonal antibody, Donor Apheresis - Lymphoma | Phase 1 | Completed | David Rizzieri, MD | 47 | 2005-05-01 | 2017-02-08 |
| Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT NK-CD56 - Lymphoma | Phase 1 | Completed | David Rizzieri, MD | 21 | 2005-04-01 | 2014-06-12 |
| Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath Campath Purged Non-myeloablative ASCT, Donor Apheresis - Lymphoma, Myeloma | Phase 2 | Completed | David Rizzieri, MD | 176 | 2003-02-01 | 2014-06-03 |
| Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Campath, Chemo and/or TBI Allo SCT - Sickle Cell Anemia, Severe Aplastic Anemia | Phase 2 | Completed | David Rizzieri, MD | 2 | 1999-09-01 | 2014-12-05 |
Lymphoma (4) · Anemia, Refractory, with Excess of Blasts (3) · Leukemia (3) · Neoplasms, Plasma Cell (3) · Hodgkin Disease (2) · Lymphoma, Non-Hodgkin (2) · Anemia, Aplastic (1) · Anemia, Sickle Cell (1) · Hemoglobinuria, Paroxysmal (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Red-Cell Aplasia, Pure (1)
Alemtuzumab (1) · Lenalidomide (1) · Rituximab (1) · plerixafor (1) · vatalanib (1)
United States (9)
David A Rizzieri, MD (2) · Anne Beaven, MD (1) · David A. Rizzieri, MD (1) · Mitchell Horwitz, MD (1)